ERBB2 and neoplasm: Recommended assessments include MMR status (by IHC and/or PCR), HER2 (by IHC; ISH if IHC is 2+), and NGS panels (DNA or RNA) that include the search for actionable tumor mutations (e.g., FGFR2, IDH1, BRAF, KRAS, and NTRK) [14,23].